NasdaqCM - Delayed Quote ? USD NLS Pharmaceutics AG (NLSPW) Follow Compare 0.0114 +0.0013 (+12.87%) At close: November 6 at 4:00 PM EST All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations NLS and Kadimastem stocks soar following merger agreement The stocks for both Swiss and Israeli biotechs were up over 20% after the companies signed a merger agreement. Pharmaceutical Technology ? yesterday NLSPW +12.87% NLS Pharmaceutics, Kadimastem enter definitive merger agreement NLS Pharmaceutics (NLSP) and Kadimastem announced that they have entered into a definitive merger agreement to combine the two companies to focus on advancing NLS’ promising, first-in class Dual Orexin Agonist platform and Kadimastem’s allogenic cell therapy program with its clinical assets. Following the closing of the transactions contemplated by the Merger Agreement, NLS intends to divest its other legacy assets, and the net proceeds of any such disposition, after deducting certain costs, fee TipRanks ? yesterday NLSP +1.24% NLSPW +12.87% NLS Pharmaceutics and Kadimastem Enter into a Definitive Merger Agreement ZURICH, SWITZERLAND and NESS ZIONA, ISRAEL / ACCESSWIRE / November 4, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP) ("NLS"), a biopharmaceutical company, and Kadimastem Ltd. (TASE: KDST.TA") ("Kadimastem"), a clinical-stage cell therapy company developing ... ACCESSWIRE ? 2 days ago NLSP +1.24% NLSPW +12.87% NLS Pharmaceutics Ltd. Regains Full Compliance with Nasdaq Listing Requirements ZURICH, SWITZERLAND / ACCESSWIRE / October 28, 2024 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP)(Nasdaq:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for ... ACCESSWIRE ? 9 days ago NLSP +1.24% NLSPW +12.87% NLS Pharmaceutics Secures Key Patent in Japan for Mazindol ER in the Treatment of Heroin Dependence ZURICH, SWITZERLAND / ACCESSWIRE / October 21, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company dedicated to developing therapies for rare and complex central nervous ... ACCESSWIRE ? 16 days ago NLSP +1.24% NLSPW +12.87% NLS Pharmaceutics Ltd. Announces Closing of Private Placement and Expected Compliance with Nasdaq Continued Listing Rules ZURICH, SWITZERLAND / ACCESSWIRE / October 15, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for ... ACCESSWIRE ? 22 days ago NLSP +1.24% NLSPW +12.87% NLS Pharmaceutics Ltd. Announces Expected Implementation of 1-for-40 Reverse Share Split ZURICH, SWITZERLAND / ACCESSWIRE / September 25, 2024 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP)(Nasdaq:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies ... ACCESSWIRE ? last month NLSP +1.24% NLSPW +12.87% NLS Pharmaceutics Signs Binding Term Sheet for Merger With Kadimastem; Shares Rise NLS Pharmaceutics Signs Binding Term Sheet for Merger With Kadimastem; Shares Rise PREMIUM MT Newswires ? 3 months ago NLSPW +12.87% NLS Pharmaceutics and Kadimastem Announce Binding Term Sheet to Merge The proposed transaction will create a Nasdaq-traded, biotechnology company with product candidates in advanced stages of clinical development and focused on advancing Kadimastem's allogeneic cell therapy platform Each of Kadimastem and NLS Pharmaceutics ... ACCESSWIRE ? 3 months ago NLSP +1.24% NLSPW +12.87% NLS Pharmaceutics Announces Registered Direct Offering ZURICH, SWITZERLAND / ACCESSWIRE / June 28, 2024 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP)(Nasdaq:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients ... ACCESSWIRE ? 4 months ago NLSP +1.24% NLSPW +12.87% Top Midday Gainers Top Midday Gainers PREMIUM MT Newswires ? 4 months ago NLSPW +12.87% DECAW NLS Pharmaceutics Announces Promising Preclinical Results for Parkinson's Disease Treatments ZURICH, SWITZERLAND / ACCESSWIRE / June 27, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company dedicated to pioneering therapies for rare and complex central nervous ... ACCESSWIRE ? 4 months ago NLSP +1.24% NLSPW +12.87% Nasdaq Panel Grants NLS Pharmaceutics' Request for Extension to Comply with Continued Listing Requirements ZURICH, SWITZERLAND / ACCESSWIRE / June 25, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a leading Swiss biopharmaceutical company dedicated to pioneering therapies for rare and complex central nervous system ... ACCESSWIRE ? 4 months ago NLSP +1.24% NLSPW +12.87% NLS Pharmaceutics Announces Publication of New Patent Application for Next-Gen Dual Non-Sulfonamide Orexin Receptor Agonists (DOXA) ZURICH, SWITZERLAND / ACCESSWIRE / June 11, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company dedicated to pioneering therapies for rare and complex central nervous ... ACCESSWIRE ? 4 months ago NLSP +1.24% NLSPW +12.87% NLS Pharmaceutics Reports Positive Results from Study KO-874 on Mazindol’s Neuroprotective Effects in Narcoleptic-like Rat Model ZüRICH, SWITZERLAND / ACCESSWIRE / May 28, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company dedicated to pioneering therapies for rare and complex central nervous ... ACCESSWIRE ? 5 months ago NLSP +1.24% NLSPW +12.87% NLS Pharmaceutics Announces Receipt of Additional Staff Delisting Determination from Nasdaq ZüRICH, SWITZERLAND / ACCESSWIRE / May 24, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients ... ACCESSWIRE ? 5 months ago NLSP +1.24% NLSPW +12.87% NLS Pharmaceutics Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request Hearing ZüRICH, SWITZERLAND / ACCESSWIRE / April 19, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for ... ACCESSWIRE ? 6 months ago NLSP +1.24% NLSPW +12.87% NLS Pharmaceutics Announces Closing of $1.75 Million Registered Direct Offering ZüRICH, SWITZERLAND / ACCESSWIRE / March 22, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for ... ACCESSWIRE ? 7 months ago NLSP +1.24% NLSPW +12.87% NLS Pharmaceutics Announces $1.75 Million Registered Direct Offering ZURICH, SWITZERLAND / ACCESSWIRE / March 20, 2024 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP)(Nasdaq:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for ... ACCESSWIRE ? 7 months ago NLSP +1.24% NLSPW +12.87% NLS Pharmaceutics Secures Exclusive Global License for Next-Generation Non-Sulfonamide Dual Orexin Agonist Platform The exclusive License Agreement grants NLS Pharmaceutics global rights to next-generation non-sulfonamide orexin-1 / orexin-2 receptor agonists, tailored to target multiple pathways in neuropharmacological therapies. Medications activating dual OX1R/OX2R ... ACCESSWIRE ? 7 months ago NLSP +1.24% NLSPW +12.87% Performance Overview Trailing total returns as of 11/6/2024, which may include dividends or other distributions. Benchmark is S&P 500 Return NLSPW S&P 500 YTD -79.64% +24.30% 1-Year -85.75% +36.04% 3-Year -98.61% +26.22%
